Eton Pharmaceuticals (NASDAQ:ETON) Upgraded at B. Riley

B. Riley upgraded shares of Eton Pharmaceuticals (NASDAQ:ETON) to a strong-buy rating in a research note issued to investors on Thursday,Zacks.com reports.

ETON has been the topic of a number of other reports. HC Wainwright raised their price objective on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, January 6th. Craig Hallum raised their price target on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $13.44 on Thursday. Eton Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $15.00. The firm has a market cap of $350.13 million, a price-to-earnings ratio of -61.09 and a beta of 1.38. The firm has a 50 day moving average price of $11.74 and a 200-day moving average price of $7.45.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth approximately $54,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals in the third quarter worth $90,000. Renaissance Technologies LLC lifted its position in Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares during the period. Stonepine Capital Management LLC purchased a new position in Eton Pharmaceuticals during the second quarter valued at $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after buying an additional 30,167 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.